Selected article for: "cell cell and infection risk"
Author: de la Cruz‐Benito, B; Lázaro‐del Campo, P; Ramírez‐López, A; de Soto‐Álvarez, T; Sánchez‐Vadillo, I; García‐Pérez, E; Dos Santos‐Ortas, A; Humala‐Barbier, K; López‐de la Guía, A; Casado‐Abad, G; Jiménez‐Yuste, V; Canales‐Albendea, MA
Title: Managing the front‐line treatment for diffuse large B‐cell lymphoma and high‐grade B‐cell lymphoma during the COVID‐19 outbreak
  • Cord-id: kacsdkr5
  • Document date: 2020_8_6
    • ID: kacsdkr5
    Snippet: The COVID‐19 pandemic has dramatically challenged care for cancer patients, especially those with active treatment that represent a vulnerable population for SARS‐CoV‐2 infection. Aggressive lymphoid neoplasms, such as diffuse large B‐cell lymphoma and high‐grade B‐cell lymphoma, need to be treated without delay in order to get the best disease outcome. Because of that, our clinical practice was changed so as to minimize risk of SARS‐CoV‐2 infection while continuing haematologica
    Document: The COVID‐19 pandemic has dramatically challenged care for cancer patients, especially those with active treatment that represent a vulnerable population for SARS‐CoV‐2 infection. Aggressive lymphoid neoplasms, such as diffuse large B‐cell lymphoma and high‐grade B‐cell lymphoma, need to be treated without delay in order to get the best disease outcome. Because of that, our clinical practice was changed so as to minimize risk of SARS‐CoV‐2 infection while continuing haematological treatment. In this report, we analyse the management of front‐line therapy in 18 patients during COVID‐19 outbreak, as well as the results of the implemented measures in their outcome.

    Search related documents:
    Co phrase search for related documents
    • active chemotherapy and lymphoma patient: 1
    • active prior and lymphocyte count: 1
    • active treatment and long outbreak: 1
    • active treatment and low incidence: 1, 2
    • active treatment and lymphocyte count: 1, 2, 3, 4, 5, 6, 7, 8, 9
    • active treatment and lymphoid malignancy: 1
    • active treatment and lymphoma patient: 1, 2
    • long outbreak and lymphocyte count: 1
    • low incidence and lymphocyte count: 1, 2, 3, 4, 5